Patents by Inventor Eva Nagy
Eva Nagy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230173148Abstract: A biomechanical breast pump mechanism (1) for expressing breastmilk comprising a biomimetic funnel (2), at least two active actuation areas (23,24) on the funnel (2) and stationary areas (25), the active actuation areas (23,24) being actuatable by a driving mechanism or mechanisms (3) and being configured to replicate the complex functions of the infant's tongue during suckling namely the physical stimulation of the areola (17)/nipple (16); nipple positioning; creating and maintaining low-level baseline vacuum to create air-seal on the breast; generating sub-atmospheric pressure inside the funnel (2); creating and maintaining close-to-zero-air environment in the funnel (2); and control of the vacuum oscillation within predefined ranges coordinated negative and positive actuation (41,42) of one or both actuation areas (23,24) independently or simultaneously.Type: ApplicationFiled: March 18, 2021Publication date: June 8, 2023Inventors: Eva Nagy-Gannon, Sandra Ganly, Yuqi Shaughnessy, Faisal Sharif, Genevieve Becker, Roy Phillip, Migle Dominica Make-Lyte, Morven Gannon, Kealan Devlin
-
Publication number: 20210317476Abstract: Described are recombinant viral vectors obtained from fowl adenovirus 9 (FAdV-9) and associated methods. The recombinant FAdV-9 vectors may include one or more deletions at the left end and/or right end of the FAdV-9 genome. Optionally, the vectors include one or more exogenous nucleotide sequences, such as sequences encoding for a polypeptide of interest. The recombinant FAdV-9 vectors may be used as a dual delivery vector. Also described is the use of the vectors for generating an immunogenic response in a subject and/or for the prevention of disease.Type: ApplicationFiled: April 29, 2021Publication date: October 14, 2021Inventors: Yanlong Pei, James Ackford, Juan Carlos Corredor, Peter J. Krell, Eva Nagy
-
Patent number: 10829786Abstract: The present disclosure relates to one or more modified avian-virus based agents, therapies, treatments, and methods of use of the modified avian-virus based agents and/or therapies and/or treatments for cancer. The disclosure also provides for methods of generating modified avian-virus based agents.Type: GrantFiled: December 14, 2018Date of Patent: November 10, 2020Assignee: ARV Pharma Inc.Inventors: Robert Kozak, Byram Bridle, Eva Nagy, Bradley Thompson
-
Publication number: 20200190538Abstract: The present disclosure relates to one or more modified avian-virus based agents, therapies, treatments, and methods of use of the modified avian-virus based agents and/or therapies and/or treatments for cancer. The disclosure also provides for methods of generating modified avian-virus based agents.Type: ApplicationFiled: December 14, 2018Publication date: June 18, 2020Inventors: Robert KOZAK, Byram BRIDLE, Eva NAGY, Bradley THOMPSON
-
Publication number: 20190153470Abstract: Described are recombinant viral vectors obtained from fowl adenovirus 9 (FAdV-9) and associated methods. The recombinant FAdV-9 vectors may include one or more deletions at the left end and/or right end of the FAdV-9 genome. Optionally, the vectors include one or more exogenous nucleotide sequences, such a sequences encoding for a polypeptide of interest. The recombinant FAdV-9 vectors may be used as a dual delivery vector. Also described is the use of the vectors for generating an immunogenic response in a subject and/or for the prevention of disease.Type: ApplicationFiled: July 11, 2016Publication date: May 23, 2019Inventors: Yanlong PEI, James ACKFORD, Juan Carlos CORREDOR, Peter J. KRELL, Eva NAGY
-
Patent number: 9119834Abstract: A high level replication fowl adenovirus (FAdV) isolate capable of reaching a viral titer of at least 3 log 10 is described. Said FAdV is a non-pathogenic strain of fowl adenovirus serotype 4, identified as FAdV-4 ON1. Additionally, the present disclosure also provides a viral vector comprising the fowl adenovirus, which has inserted an exogenous nucleotide sequence coding for at least one antigenic site of a disease of concern, as well as a method for obtaining said viral vector and an immunogenic composition comprising the same.Type: GrantFiled: March 16, 2012Date of Patent: September 1, 2015Assignee: University of GuelphInventors: Éva Nagy, Bryan Griffin, Helena Grgic, Davor Ojkic
-
Publication number: 20140010834Abstract: A high level replication fowl adenovirus (FAdV) isolate capable of reaching a viral titer of at least 3 log 10 is described. Said FAdV is a non-pathogenic strain of fowl adenovirus serotype 4, identified as FAdV-4 ON1. Additionally, the present disclosure also provides a viral vector comprising the fowl adenovirus, which has inserted an exogenous nucleotide sequence coding for at least one antigenic site of a disease of concern, as well as a method for obtaining said viral vector and an immunogenic composition comprising the same.Type: ApplicationFiled: March 16, 2012Publication date: January 9, 2014Applicant: University of GuelphInventors: Éva Nagy, Bryan Griffin, Helena Grgic, Davor Ojkic
-
Publication number: 20130089564Abstract: Provided is an immunosuppressive peptide of 40 kDa molecular weight, isolated from the submandibular glands (SMG*) of rats, having the capacity to suppress immune reactions upon parenteral administration to rats and mice. The peptide was identified as glandular kallikrein (K1) by partial sequencing and by enzymatic activity. Also provided are methods and compositions for Using K1 peptides in the treatment of autoimmune diseases.Type: ApplicationFiled: August 21, 2012Publication date: April 11, 2013Applicant: DIAMEDICA INC.Inventors: Istvan Berczi, Edris Sabbadini, Eva Nagy
-
Patent number: 8383115Abstract: The present disclosure describes a single chain variable fragment (scFv) that binds BHV-1 virus comprising a light chain variable region, a linker and a heavy chain variable region. The disclosure also describes nucleic acid molecules encoding the scFv molecules, methods and uses thereof for treating or neutralizing BHV-1 infection and diagnostic methods, agents and kits thereof.Type: GrantFiled: July 18, 2008Date of Patent: February 26, 2013Assignee: Azad Kumar KaushikInventors: Azad Kumar Kaushik, Madhuri Koti, Eva Nagy
-
Publication number: 20100196375Abstract: The present disclosure describes a single chain variable fragment (scFv) that binds BHV-1 virus comprising a light chain variable region, a linker and a heavy chain variable region. The disclosure also describes nucleic acid molecules encoding the scFv molecules, methods and uses thereof for treating or neutralizing BHV-1 infection and diagnostic methods, agents and kits thereof.Type: ApplicationFiled: July 18, 2008Publication date: August 5, 2010Inventors: Azad Kumar Kaushik, Madhuri Koti, Eva Nagy
-
Publication number: 20070224209Abstract: An immunosuppressive peptide of 40 kDa molecular weight, isolated from the submandibular glands (SMG*) of rats, had the capacity to suppress immune reactions upon parenteral administration to rats and mice. The peptide was identified as glandular kallikrein (K1) by partial sequencing and by enzymatic activity. Further experiments revealed that the excision of SMG (SMGx) from Lewis rats prevents the oral induction of immunological tolerance against native bovine type II collagen (BCII). Thus SMGx rats, when they were given oral BCII and were subsequently immunized with the same antigen, developed collagen induced arthritis (CA), while normal rats given an identical treatment were protected from the disease. When SMGx rats were orally given porcine K1 in conjunction with BCII, the capacity of such animals to develop oral tolerance was fully restored. These results indicate that normal SMG function is required for induction of oral tolerance and that K1 is involved in mediating this function.Type: ApplicationFiled: February 12, 2007Publication date: September 27, 2007Applicant: The University of ManitobaInventors: Istvan Berczi, Edris Sabbadini, Eva Nagy
-
Patent number: 7195759Abstract: An immunosuppressive peptide of 40 kDa molecular weight, isolated from the submandibular glands (SMG*) of rats, had the capacity to suppress immune reactions upon parenteral administration to rats and mice. The peptide was identified as glandular kallikrein (K1) by partial sequencing and by enzymatic activity.Type: GrantFiled: June 6, 2002Date of Patent: March 27, 2007Assignee: The University of ManitobaInventors: Edris Sabbadini, Eva Nagy, Istvan Berczi
-
Publication number: 20030216306Abstract: An immunosuppressive peptide of 40 kDa molecular weight, isolated from the submandibular glands (SMG*) of rats, had the capacity to suppress immune reactions upon parenteral administration to rats and mice. The peptide was identified as glandular kallikrein (K1) by partial sequencing and by enzymatic activity. Further experiments revealed that the excision of SMG (SMGx) from Lewis rats prevents the oral induction of immunological tolerance against native bovine type II collagen (BCII). Thus SMGx rats, when they were given oral BCII and were subsequently immunized with the same antigen, developed collagen induced arthritis (CA), while normal rats given an identical treatment were protected from the disease. When SMGx rats were orally given porcine K1 in conjunction with BCII, the capacity of such animals to develop oral tolerance was fully restored. These results indicate that normal SMG function is required for the induction of oral tolerance and that K1 is involved in mediating this function.Type: ApplicationFiled: June 6, 2002Publication date: November 20, 2003Inventors: Edris Sabbadini, Eva Nagy, Istvan Berczi
-
Patent number: 5788964Abstract: The invention relates to a method of sensitizing cancer cells for a killer cell mediated lysis which involves administering to a patient an effective amount of antiestrogen and killer cells either jointly or sequentially, wherein the killer cells are selected from the group of NK cells, LAK cells and CTL cells and the antiestrogen is selected from the group of triphenylethylene class antiestrogens, such as tamoxifen or toremifene or their pharmaceutically acceptable salt.Type: GrantFiled: April 15, 1996Date of Patent: August 4, 1998Assignee: Orion-Yhtyma OyInventors: Edward Baral, Istvan Berczi, Eva Nagy, Lauri Kangas